A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

QuidelOrtho Corporation QDEL

Mixed broader-coverage candidate · QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands.

On FrontierLab's discovery record since 2026-06-29 (7 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)

Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Mixed" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-08-15), not the curated Frontier signal.

Key quality signals

Revenue growth (YoY)	-2.5%
Gross margin	44.6%
Gross profits / assets	0.21
Rule of 40	-33.2
Net margin	-30.7%
Cash runway (months)	25.9
PEG	—
Price / sales	0.4

Quality checklist

✗ Revenue growth — -2.5% (pass ≥ 20%)
~ Gross profits / assets — 0.21 (pass ≥ 0.33)
~ Gross margin — 44.6% (pass ≥ 60%)
~ Cash generation
✓ Share dilution — 0.9%

Fundamentals — snapshot as of 2026-08-15

Stage	Established
Share issuance (YoY)	0.9% · flat share count
Moat	—
TAM	—
P/E (trailing)	—
EPS (trailing)	$-15.44
Burn multiple	0
Gross-margin trend (pts)	-2.7
Cash / assets	0.02
Net debt / EBITDA	—
Statements as of	Q2 FY2026 · filed 2026-08-07

Momentum context — a snapshot from 2026-08-15, not current

Price at surface	$14.30 (as of 2026-08-15)
52-week range	$9.92 – $35.58
% off 52-wk high	-59.8%
RSI (14)	42
Relative volume	0.6×

Risk flags

Burning cash — operating margin is negative.

← All broader-coverage names · Curated names → · Open the interactive screener →

Data as of 2026-08-15 (end-of-day). How grades are computed →